International Journal of Pharmaceutical Research and Applications
Volume 8, Issue 3 May-June 2023, pp: 2703-2717 www.ijprajournal.com ISSN: 2249-7781

Approaches to the Polymeric Nanoparticles

Purva Patil[1], Neha Baglane[2], Priya H. Kapase[3], Radhika Baheti[4]
1,2,3,4 SSP, Shikshan Sanastha's Siddhi College of Pharmacy, Newale vasti, Chikhali, 411061

Submitted: 09-06-2023 Accepted: 19-06-2023

ABSTRACT: Nanomaterials (NMs) have risen in importance as a result of their tunablephysiochemical and biological characteristics, as well as the outstanding quality in contrast to their size counterparts. The objective of this review is to identify the methods used to create nanoparticles. Additionallydifferent types of nanoparticles are classified based on the vehicle used to deliver them. In the review, various methods for classifying nanoparticles are presented, along with an overview of the polymers used in their preparation. Additionally, the characterization of polymeric nanoparticles and their preparation methods are also compiled.

KEYWORDS: Polymers, Nanoparticles, Lipids, Methods, Preparation, dimension, Emulsification, spectroscopy

I. INTRODUCTION:-

In comparison to bulk materials with the same composition, nanoparticles (NPs) are minuscule particles, measuring 1000 nmwith distinctive physicochemical properties. The use of NPs in both commercial and medical research is highly desirable due to these qualities. [[1]]

Since polymeric NPs possess capacity to regulate release, protect drugs using the environment and other molecules with biological activity, and boost bioavailability and therapeutic index, they can be used as drug carriers. The term "nanoparticle" encompasses both the two subtypes of nanoparticles, nanospheres and nano capsules. The release of drug from the oily component in nano capsules is controlled by a polymeric shell that surrounds the core, which is typically dissolved with the drug. Due to the continuous polymeric network of nanospheres, drugs can be kept inside of them or Entrapped by their area. The two different polymeric NPs forms are referred to as matrix system (nanosphere) and a reserve system (nano capsule). [[2]]Nanoparticles are produced using two fundamental methods: bottom-up method and top-down method.

Top-Down/mechanical-physical production processes

Procedures for producing mechanical-physical molecules based on microsystem technology principles are referred to as "top-down" processes.One of the traditional mechanical-physical crushing techniques for the generation of nano particles is milling.

Bottom up/Chemo-physical production processes

The physicochemical principles of self-organization in molecules or atoms serve as the foundation for bottom-up methodsfrom molecules or atoms, this methodproduces a few more intricate structures that are easier to control in terms of size, shape, and range. Included are solgel processes, precipitation reactions, and aerosol processes. [[3]]

1 Types of Nanoparticles

The following three categories can be roughly categorized as:

1. Polymer Nanoparticles
2. Nanoparticles onlipid based
3. Lipid-polymer combination Nanoparticle

International Journal of Pharmaceutical Research and Applications
Volume 8, Issue 3 May-June 2023, pp: 2703-2717 www.ijprajournal.com ISSN: 2249-7781



Chart 1:- Types of different nanoparticles

1. Polymer-based nanoparticles

Depending on how they have been developed, these can be either nanospheres or nano capsules. In contrast, the drug is contained in nanospheres, which are matrix systems and physically. Dispersed,the drug is contained in systems known as nano capsulescontained within a cavity that is surrounded by an individual polymer membrane. [[5], [6], [7]]

1.1 By using Ionotropic Gelation Method or byIonic Cross-Linked Method:

Biopolymer nanoparticles produced through the ionotropic gelation were initiated by Calvo et al.[8]In this method, the chitosan amine group interacts electrostatically with a negatively charged poly anion group, such as tripolyphosphate. [[9], [10], [11]] Nanoparticles spontaneously formed after the addition of poly anion or anionic polymer while still being mechanically stirred at room temperature. (Fig. 2) [[12]]

1.2 Micro emulsion Method/Covalent Method of Cross-Linking

Using a micro emulsion technic, Maitra et al. were the first to generate a nanoparticle from chitosan. [[15]]The foundation of this procedure isChitosan is constructed by glutaraldehyde as well as amino group cross-linking within the molecular chain the covalent cross-linking of the chitosan chain utilized asa suitable cross-linking agent. Nanoparticles encasing 5-fluorouracil were first created using this method.[[16]]

n-Hexane was dissolved in a surfactant using the micro emulsion method. Before adding glutaraldehyde and chitosan in an acetic solution, the surfactant/hexane mixture was first continuously mixed at room temperature for a period of moment. Nanoparticles developed as a result of surfactant. The cross-linking of chitosan includes a combination of the glutaraldehyde and the free amine group. The system began to tremble overnight. The organic solvent is consequently eliminated while dealing with low pressure through evaporation. By changing the glutaraldehyde concentration, which also changes the degree of cross-linking, particle size can be controlled. This technique uses a 100 nm size distribution. [[17]]

1.3 Polyelectrolyte Complex Method

When poly anions and a cationic, charged polymer self-assemble, polyelectrolyte complexes, also described as self poly electrolytes, take shape.

International Journal of Pharmaceutical Research and Applications
Volume 8, Issue 3 May-June 2023, pp: 2703-2717 www.ijprajournal.com ISSN: 2249-7781

Several chitosan nanoparticle formulations that use polyelectrolyte complexation call for the use of poly-cationic and poly-anionic polymeric materials in addition to chitosan. No additional particles, for eg catalyst or initiator, are typically usually required for the reaction, that also typically takes place in an aqueous solution.

1.4By using Emulsion Solvent Evaporation Method

Among the latest common process for drug encapsulation in not soluble in water these polymers used in this technique. [[23]]Alginate, a biodegradable and biocompatible copolymer, is achieved by a combination of guar and mannuronic acid. The frontline anti-tubercular drugs (ATDs; pyrazinamide, thambutol, isoniazid, and rifampicin) have been supplied using it as a nanoparticulate delivery system. It is frequently taken orally to treat reflux esophagitis. [[22]]

1.5 Complex Coacervation Method

The detachment of polymer solutions into two coexisting phases using coacervation techniques results in a diluted steady state phase or filtrates that is free of polymer matrix and a thick amplification phase that is filled up with polymer matrix. In aqueous systems, coacervation comes in two forms: simple coacervation and complex coacervation. Electrostatic attractions cause complex coacervation, which merge colloids with opposing charges, to spontaneously separate into liquid and liquid phases. [28]

1.6 Self-Assembly Method

Amphiphilic compounds can fully capable into core shell NPs in water. Amphiphilic NPs can simultaneously travel hydrophilic and hydrophobic drugs thanks to their hydrophilic shell and hydrophobic core. One advantage of the water loving shell is that it lessens the engulfment of macrophages. Tien et al.'samphiphillicNPs have consequently drawn growing attention described how to make hydrophobic self-assembling N-acylated microparticles for product-controlled release.[[28]]

2. Lipid-Based Nanoparticles

Lipid nanoparticles are spherical, biocompatible, biodegradable, nanoscale particles that are made of lipids. Lipid nanoparticles can be made by adding phospholipids as emulsifiers to an oil phase, such as triolein. For instance, paclitaxel may be added to the oily core.[**Error! Reference source not found.**, [31]] High-pressure homogenization, a process used to start creating liposomes, is one that can be used to them. Fig.2.

2.1 Solid lipid Nanoparticles (SLN)

A Solid Lipid Nanoparticlesis a different choice to the colloidal particles from pastcarriers like Liposomes, micro- and nanoparticles, and emulsions made of polymers which was first presented in 1991. The right surfactant or surfactants stabilize the SLN structures, which withstand well at both room and body temperatures. These lipidic compounds include waxes, complex glyceride mixtures, and purified triglycerides. [[33], [34]]High-speed homogenization, micro emulsions, emulsion solvent evaporation, and ultra-sonication are a few examples of how these can be made, membrane contractor technique, phase inversion, and solvent injection.

2.2 Nanostructured Lipid Carriers (NLC)

Toward the end of the 1990s, NLC was introduced, which remedied the drawbacks of SLN. NLCs are constructed by combining lipids from both the solid and liquid phases. NLC can be free in 3 different ways depending on the make-up of their lipid matrix; the amorphous type or structure free type, the imperfect type, and the multiple types. The drug's compartments and lipid matrix may have faults because the lipid is either saturated or unsaturated and has different fatty acid chain lengths. Drugs were surrounded by Bio Nano Science in a solid lipid nanoparticle. [[29]]

2.3 Lipid drug conjugates (LDC)

Lipid Drug Conjugate NP's helps in easy incorporation of drug up to 33%. It is possible to build by salt formation, toa bulky drug-lipid conjugate that's also insoluble (for example-,utilizing a fatty acid) or covalently linked (for esters and ethers). During the process of making fatty acid, salt and free drug base are solubilized in an appropriate mixture. As a result, the solvent is thereafter vaporized at a lower pressure. Recrystallization is used to detoxify the LDC bulk after the drug (salt) and fatty alcohol undergo a covalent linking reaction. Finally, a nanoparticle is produced by homogenization using a high-pressure aqueous surfactant solution to combine the obtained LDC bulk.[[36]]

3 Lipid polymer hybrid Nanoparticles

International Journal of Pharmaceutical Research and Applications
Volume 8, Issue 3 May-June 2023, pp: 2703-2717 www.ijprajournal.com ISSN: 2249-7781

In the lipid polymer hybrid NPs, the perks ofindividual lipid and polymer based nanoparticles are combined. [43, 44, 46]The drug distribution platform of LPN is robust, with a more drug deposition yield,excellent serum stability, a drug release profile that is customizable and sustained, andcontrasting cell or tissue target. There were three distinct functional parts to the LPN: 1) a polymer core that is hydrophobic and used to deposit drugs that are difficult to dissolve in water; (2) a polymer hydrophilic shell with anti-bio fouling properties that increase LPN half-life in systemic circulation and improve LPN stability; (3)a lipid trying to act as a molecular shell at the core-shell interfaceto encourage drug absorptionwithin the polymeric core and enhance drug deposition efficacy, drug release and drug loading yield control.[[38]]

Covalent bonds frequently join the lipid shell to the hydrophilic polymeric shell. It has been demonstrated that these lipid–polymer hybrid nanoparticles possess the distinct while avoiding some of their inherent drawback; polymer- and lipid-based nanoparticles have several advantages. As a result, they have a lot of potential as a delivery method for various medical uses. [[40]]

TYPES OFPolymeric Nanoparticle	**EXAMPLES**
1.Polymer Nano particles	Drug conjugates, nanoparticles, micelles, nanogels, proteins, as well as dendrimers
2.Lipid Nano Particles	Solid lipid nanoparticles, exosomes, and liposomes
3.NonPolymeric Nanoparticles	Nanoparticles created of silica, carbon nanotubes, diamond, metallic nanoparticles, and quantum dots
4.Nanocrystalline	Chitin, Chitosan

Table 2:- Different Types of Nanoparticles Based On different Formation [48]

Fig 2:- Lipid Nanoparticle

International Journal of Pharmaceutical Research and Applications
Volume 8, Issue 3 May-June 2023, pp: 2703-2717 www.ijprajournal.com ISSN: 2249-7781

2 Polymers used in nanoparticles preparation

2.1 Polyglycolide

Polyglycolide has excellent mechanical qualities like a high tensile modulus because it is a polymer with a high crystallinity (45–55%). In organic solvents, it was very difficult to dissolve. A temperature of this polymer's glass transition is between 35 and 40 degree Celsius, and its melting point is above 200 degree Celsius. Disadvantages of polyglycolide, including its low solubility, rapidspeed of deterioration, and acidic deterioration products, restrict its use in biomedicine. In order to circumvent these concerns, a number of copolymers with glycolide blocks are being created.

2.2 Poly lactic acid (PLLA)

The polymer processing parameters and molecular weight determine the degree of crystallinity of PLLA, which has a crystallinity of 37%. That substance hadtemperature at which glass shifts between 60-65 degree Celsius, andits melting point was 175 degree Celsius. Polyglycolide breaks down faster than PLLA, a polymer. Low extension, a high modulus, and a powerful in tensile terms are just a few of its desirable mechanical properties.

2.3 Poly lactic co-glycolic acid(PLGA)

Lactic and glycolic acid copolymers have drawn a lot of attention as drug delivery transport in the field of biopolymers. In general, there are two methods for creating PLGA copolymers: A. By directly polycondensing glycolic and lactic acid; B. by lactic acid (lactide) and glycolic acid (glycolide)opening cyclic dimers in polymerization. Copolymers made using the second method have higher molecular weights and superior mechanical properties than copolymers made using the first method. Since lactide is less hydrophilic than glycolide, PLGA copolymers have a lower rate of degradation with a rising lactide to glycolide ratio. PLGA has a high rate of hydration and hydrolysis because it is less crystalline thanPGA and PLLA.

2.4 Poly caprolactone (PCL)

PCL is a hydrophobic, with a semi-crystalline polymer 60° transition temperature for glass (TG) degrees Celsius and a melting point of 59 -64 degrees Celsius. [[42], [43]]With the aid of a number of anionic, cationic, and coordination catalysts, including the -caprolactone monomer, PCL is produced using the ring-opening polymerization method with the aid of a number of anionic, cationic, and coordination catalysts, including the caprolactone monomer, PCL is produced through the ring-opening polymerization process. We make use of 4-vinyl anisole, polyvinyl chloride,Diisocyanates (urethanes), vinyl acetate, polyethylene glycol (PEG), polystyrene, chloroprene, and polyethylene glycol (PEG). [[43], [47], [48], [49], [50]]

4.There also are various approaches for classification of nanomaterials.According to Hett (2004), nanoparticles are categorized as below.

4.1. One dimension nanoparticles

Thin films and manufactured surfaces are explanations of one-dimensional systems that have long been used in engineering, chemistry and electronics. Making of thin films or monolayers (sizes 1-100 nm) is currently standard practice in the fields of solar cells and Catalysis. These films are used for a variety ofapplications for technology, such as data storage systems and chemical and so more. Biological sensor, fiber optic system, magneto-optic devices.

4.2.Two dimension nanoparticles

4.2.1 Carbon nanotubes (CNTs):

The CNTs are atoms in ahexagonal structure in a carbon molecule with 1 nm diameter and that are 100nm in length created by rollingup a graphite layer into a cylindrical tube. CNTs come in two varieties: SWCNTs, or uni wall carbon nanotubes, and MWCNTs, orvaryingly walled carbon nanotubes. Nanotubes have an extremely high current density—approximately 1 billion amperes per square meter—which helps make them a superconductor. Comparison to the strongest steels, carbon nanotubes have a mechanical strength that is sixty times greater. Molecular absorption is significantly improved by the three-dimensional structure of carbon nanotubes. They are also extremely chemically stable.

4.3.Three dimension nanoparticles

4.3.1 Fullerene (C 60):

Round cages, fullerenes comprisingC60 is composed of 28 to more than 100 carbon atoms. An empty soccer ball closely resembles pentagons and hexagons of carbon connected to each other the class of materials known as fullerenes have distinctive physical properties. They can be put under a lot of pressure and then get back to how

International Journal of Pharmaceutical Research and Applications
Volume 8, Issue 3 May-June 2023, pp: 2703-2717 www.ijprajournal.com ISSN: 2249-7781

they were before the pressure was applied. Because these molecules do not combine, they have a lot of potential for use as lubricants.Their intriguing electrical properties have led to the suggestion that they be used in the electronic sector, including data storage and solar cell production. The application of fullerenes in a number of nano electronicuses is possible. Due to their empty structure and dimensions that are such as of a number of bioactive molecules, fullerenes have the potential to be used in medicine (Tomalia, 2004).

4.3.2 Dendrimers:

A product class of polymers with controlled structures a nanometric size is called dendrimers. Because they typically have a surface with numerous functional groups and a diameter between 10 and 100 nm, dendrimers are excellent drug delivery vans (Wiener et al., 1994). They cooperate well with organic materials structures like DNA can be created into metallic nanostructures, nanotubes, or other shapes (Fu et al., 2007). Due to their compatibility with organic structures like DNA and their various reactive surface groupings (nanostructure), dendrimers are frequently used for biological and medical fields.

4.3.3 Quantum Dots (QDs):

In quantum dots, a very small device, there isa microscopic drop of unbound electrons. Colloidal semiconductor nanocrystals are known as QDs. with diffraction pattern of 2 to 10 nm. A variety of semiconductor materials can be used to make QDs throughelectrical engineering or electrochemistry. Themajority frequently utilizedQDs are made of indium phosphide (INP), cadmium selenide (CdSe), and indium arsenide (InAs). Optical and optoelectronic devices, as well as information storage, can all be decided to make with it. DNA testing is done quickly using quantum dots that are color-coded. Quantum dots (QDs) are objects where carriers of electrons and holes are quantum-confined at sizes smaller than the Bohr radii. [[53]]

5.Method of preparation of nanoparticles:

5.1 Solvent Evaporation:[0[55]]

Solvent evaporation was the initial technique used to createan already-formed polymer, polymeric NPs. This approachrequires the initial creation of o/w emulsion. Even though previously used more frequently, chloroform and dichloromethane are still widely used today. [[57]]Considering their toxicity better toxicological profile, ethyl acetate and is that's why better suitedfor biomedical purposes, has removed them. [58]It has also been normal practice to prepare a water stage that containsa surfactant like PVA (polyvinyl acetate). [[59]]

The natural remedy had been stirred with both the water state using a surfactant to emulsify it. To create a dispersion of nano droplets, usually, it is processed again viaultrasound or quick homogenization.[[60]]As the polymer solvent evaporates, the NPs are able to dissipate through the emulsion's continuous phase and form a suspension. When using morePolar solvents (like dichloromethane and chloroform), either the solvent slowly vaporizes under low pressure or shaken vigorously magnetically while at room temperature. The crystallized if the solvent has been removed, nanoparticles can be collected, disappeared, collected by centrifugation and freeze-driedfor long-term backing up. This technology can be used to generate nanospheres. [[61]]

5.1.1Emulsification/Solvent Diffusion:

An oil in water emulsion is developed by adding surfactant-containing aqueous solution with a drug and polymer-including partially water-miscible solvent. [[62],[63]]A partially flammable organic solvent hydro-miscible with water, like benzyl alcohol or ethyl acetate, tends to make up the. AStage inside of this emulsion.This creates thermodynamic equilibrium between the two phases at room temperature.[[64]]Trace quantity of oil (triglycerides, for e.g.) can be added to the mixture to create nanocapsules. Regardless of the fact that this is the usual way to create nanospheres. [[65]]

5.1.2Emulsification/Reverse Salting Out

The emulsification method uses lead to formation salting-out effect to separate an aqueous solution from a hydro-miscible solvent, which can of nanospheres.[[66]]The O/W emulsion is made of a polymer solvent that dissolves in water, like acetone or ethanol, which is the main difference.A salting out agent, a colloidal stabilizer and gel also evident in the water phase. [[67]]Good salting out encompass electrolytes like MgCl2 and CaCl2, but also Mg(CH3COO)2 along with non-electrolyte like sucrose. [[69], [70]]

5.2 Nanoprecipitation:

This procedure, also referred towhen the solvent is shifted necessitatesa pair of soluble

International Journal of Pharmaceutical Research and Applications
Volume 8, Issue 3 May-June 2023, pp: 2703-2717 www.ijprajournal.com ISSN: 2249-7781

solvents. The internal phase is a dissolved polymer in an organic miscible solvent including acetone or acetonitrile. [[71], [72], [73]]Evaporation makes it simple to get rid of them even though they are immiscible in water. The basis of this method is the polymers inter - facial deposition subsequently the removal regarding the organic solvent is shiftedin the liquid media from a lipophilic solution. [[76]]After the polymer has beenbroken down in an intermediately polar solvent that mixture is applied water miscible, the solution either at a controlled rate or stepwise (in a dropwise fashion) into an aqueous solution while being stirredthe polymer solution's quick sudden diffusion into the water phase. which arises in an effortto keep the water molecules at bay, provokes the nanoparticles to form right away. [[77]] Asthe fluid dissipates of the nano droplets, the polymer precipitate in the form of nanospheres or nanocapsules. [[80]]

6. Characterization of polymeric nanoparticles:-

6.1 Transmission Electron Microscopy (TEM)

Standard transmission electron microscopy has problemstructuring resolutionat the nanoscale. Although, electron microscopy methods can be used to examine these nanostructures in greater depth. TEM and SEM are the twomost widely used methodsfor conducting electron microscopy. They both will offer the same kind of data. By guidingan electron beam passing by a test object, a TEM produces the image.After that, the picture is enlarged and able to focus ona visualization tool. As a result, information is gathered.[[81],[82], [83],[84]]

6.2 Scanning Electron Microscopy (SEM)

A Scanning electron microscopy is a particular kindusing an electron microscope detects a sample area with a concentratedan electron flow to capture picture of it. When electron interacts in a test of atoms, distinct signals are generated that provide details in regards to surface topographic features and composition of the sample. SEM appliedto ascertain the morphology, size, and shape of polymeric nanoparticles. Likewise, it might reveal the level of PNP aggregation. [[84],[85]]

6.3 Atomic force microscopy (AFM)

Atomic force microscopy is a method that is applied to study the morphological characteristics of polymeric NPs surfaces. It is helpful for investigating exterior morphological characteristics at the nano scale in addition to measuring delicate forces. [[84], [85]]

Fig:- 3 Atomic Force Microscopy

International Journal of Pharmaceutical Research and Applications
Volume 8, Issue 3 May-June 2023, pp: 2703-2717 www.ijprajournal.com ISSN: 2249-7781

6.4 Light Scattering Techniques

In light scattering experimentations, the sample is first highlighted by a monochromatic beam. Once the light has been scattered, a detector records it at a particular angle. As a result, the characteristics of the sample are looked at 3 fundamental light transmitting strategies help to define polymeric NPs.

6.5 Dynamic Light Scattering (DLS)

DLS is serves to estimate a nanoparticle's size in a solvent. DLS and spectra of photon correlations can be used to estimate particle size. The particles' Brownian motion is the basis of it a basic stage in A DLS experiment consists of shining a monochromatic laser beam on a colloidal mixture.After that, a photo detector obtains the scattered light. The scattered light intensity variations with time due to particles Brownian motion. The particle size is linked to this temporal variation in light intensity by an autocorrelation function. Therefore, DLS can be used to estimate the size of particles. [[87]]

6.6 Electrophoretic Light Scattering (ELS)

Electrophoretic light scattering is focused on dynamic light scatter dynamic light scattering. DLC can be used to calculate zeta potential and ELS can be used to measure electrophoretic mobility to determine particle size. This method is the most effective one for calculating zeta potential. In actuality, the zeta potential of colloidal solutions is used to gauge their stability. It also tends to help with surface property analysis. 5 As a result, readings between -30 mV and +30mV signify aggregation, flocculation, precipitation, or instability. Due to particle aggregation, electric repulsion isat a high zeta potential reduced value.[[88]]

6.7 Fourier Transform Infrared Spectroscopy (FTIR)

It is a technique of spectroscopy, tracks transitions the vibration among variousstates of molecular excitation. This approach is more effective to learn about the architectural characteristics of PNP. Studyingthe exchangesof particles among thepharmaceuticals and thetaking up polymeris also beneficial. In actuality, known compounds can be found using the fingerprint region. Aside from that, we can spot impurities. (fig. 4)

Fig.4FTIR

6.8 UV-Visible spectroscopy

NPs had distinctive visual characteristics these characteristics of NPs have impacted by their size, shape, concentration, and agglomeration. As a result, UV-Visible spectroscopy is an appropriate process for characterizing and defining polymeric nanoparticles. Using a spectroscopy technic, the quantity of light that the sample absorbed is used to calculate the analyte concentration. [[89]]

6.9 X-ray Photoelectron Spectroscopy (XPS)

A procedure for figuring out ia material's surface chemistry s called XPS. It is able to determine the chemical, electronic and elemental states of a material a robust surface is first exposed to a beam of X-ray in XPS. Electrons are subsequently excited to various energies. Then, it is determined how much kinetic energy was

International Journal of Pharmaceutical Research and Applications
Volume 8, Issue 3 May-June 2023, pp: 2703-2717 www.ijprajournal.com ISSN: 2249-7781

released by the electrons from the top 1 to 10nm of material. It will be useful in figuring out the elements' make-up.

6.10 Fluorescence Spectroscopy

The fluorescence of a sample is examined using a spectroscopy method called as fluorescence spectroscopy. It also goes by the name fluorimetry. The process includes causing the electrons of a specific compound to be excited by a beam of light, usually ultraviolet light. And hence, these substances will emit light. 10 For instance, it's used to study how nanoparticles and conformational changes in biomaterials interact. [[88]]

6.11 Diffraction Techniques

With the aid of diffraction techniques, the sample's crystal structure can be studied. For this, XRD analysis is commonly used.[[90], [91]]

6.12 X-ray Diffraction (XRD)

The efficient technique of XRD could be help to investigate theNPs' crystal structure. It is used to conduct the initialidentification of materials propertieslikeCrystallite, crystal structure strain and size. In actuality, based on the crystal's structure and the wavelength of theinteraction with light, a variety of diffraction patterns can be observed. The periodic structure's interference of light from reflected objects distinct material layers is what causes diffraction.[[90]]

II. CONCLUSION

In the quickly growing modern technical area known as "polymer in the delivering of smart medications," numerous medicinal applicationsare anticipated to address patient concerns in the field of medicine. They are recognized as controlled, targeted, multi-functional, and environment-responsive drug delivery system and hence Polymeric Nano-particles (PNP) hasvarious promising and useful interactive frameworks.

PNPs' physiochemical characteristics need to be revised for the specific application. Different polymers can be used in a variety of ways to create various nano-particulate systems. Nano hydrogels, micelles that adapt to their environment, NPs with a core, and colloids, nanospheres, and core shell nanospheres are a few examples of multifunctional PNPs that have already been developed for single, dual, or multiple drug release.The synthesis approach's mechanism is essential in achieving the necessary features.

REFERENCES:-

[1]. Medina, C., Santos-Martinez, M. J., Radomski, A., Corrigan, O. I., & Radomski, M. W. (2007). Nanoparticles: pharmacological and toxicological significance. British journal of pharmacology, 150(5), 552–558.

[2]. Zielińska A, Carreiró F, Oliveira AM, Neves A, Pires B, Venkatesh DN, et al. Polymeric Nanoparticles: Production, Characterization, Toxicology and Ecotoxicology. Molecules [Internet] 2020; 25(16):3731. Available from: http://dx.doi.org/10.3390/molecules25163731

[3]. How Nanoparticles are made,https://www.nanowerk.com/how_nanoparticles_are_made.php, 15 Feb, 2023

[4]. Preethi, Sayantani Dutta, J.A. Moses, C. Anandharamakrishnan, Chapter 8 - Green nanomaterials and nanotechnology for the food industry, Editor(s): Uma Shanker, Chaudhery Mustansar Hussain, Manviri Rani, In Micro and Nano Technologies, Green Functionalized Nanomaterials for Environmental Applications, Elsevier, 2022, Pages 215-256, ISBN 9780128231371, https://doi.org/10.1016/B978-0-12-823137-1.00008-7.

[5]. Langer, R. (2000). Biomaterials in drug delivery and tissue engi-neering: one laboratory's experience. Accounts of Chemical Re-search, 33(2), 94–101. doi:10.1021/ar9800993.

[6]. Bhadra, D., Bhadra, S., Jain, P., Jain, N. K. (2003). A PEGylateddendritic nanoparticulate carrier of fluorouracil. International Jour-nal of Pharmaceutics, 257(1–2), 111–124. doi:10.1016/S0378-5173(03)00132-7.

[7]. Kommareddy, S., Tiwari, S. B., Amiji, M. M. (2005). Long-circulating polymeric nanovectors for tumor-selective gene deliv-ery. Technology in Cancer Research & Treatment, 4(6), 615–625. Various types of polymer-based nanoparticles are rendered

[8]. Calvo, et al. (1997). Novel hydrophilic chitosan-polyethyleneoxide nanoparticles as protein carriers. Journal of Applied Poly-mer Science, 63, 125–132. Doi:0021-8995/97/010125-08.

[9]. Bodmeier, R., Chen, H.G., Paeratakul, O. (1989). A novel approachto the oral delivery of micro- or nanoparticles. PharmaceuticalResearch, 6(5), 413–417. doi:10.1023/A:1015987516796

[10]. Pan, Y., Li, Y. J., Zhao, H. Y., Zheng, J. M., Xu, H., Wei, G., Hao, J.S., Cui, F. D. (2002). Bioadhesive polysaccharide in protein deliv-ery system: chitosan nanoparticles improve the intestinal absorptionof insulin in vivo. International Journal of Pharmaceutics, 249(1–2), 139–147. doi:10.1016/S0378-5173(02)00486-6.

[11]. Dustgani, A., Fasahani, E. V., Imani, M. (2012). Preparation and invitro characterization of chitosan nanoparticles containing Mesobu-thus eupeus scorpion venom as an antigen delivery system. Journalof Venomous Animals and Toxins including Tropical Diseases, 18(1), 44–52. doi:10.1590/S1678-91992012000100006.

[12]. Shi, L. E., & Tang, Z. X. (2007). Adsorption of nuclease p1 on chitosan nano-particles. Brazilian Journal of Chemical Engineer-ing, 26(2), 223–228. doi:10.1590/S0104-66322009000200022.

[13]. Tsai, M. L., Bai, S. W., Chen, R. H. (2008). Cavitation effects versus stretch effects resulted in different size and polydispersityof ionotropic gelation chitosan-sodium tripolyphosphate nano-particle. Carbohydrate Polymers, 71(3), 448–457

[14]. Sarmento, B., Ribeiro, A. J., Veiga, F., Ferreira, D. (2007). Alginate/chitosan nanoparticles are effective for oral insulin delivery. Pharmaceutical Research, 24(12), 2198–2206. doi:10.1007/s11095-007-9367-4.

[15]. Maitra, A. N., Ghosh, P. K., De, T. K., Sahoo, S. K. (1999) Process for the preparation of highly mono dispersed hydrophilic polymeric nanoparticles of size less than 100 nm. US patent5,874,111

[16]. Ohya, Y., Shiratani, M., Kobayashi, H., Ouchi, T. (1993). Releasebehavior of 5-fluorouracil from chitosan-gel nanospheres immobilizing 5-fluorouracil coated with polysaccharides and their cell specific cytotoxicity. Journal of Microencapsulation, 10(1), 1–9.doi:10.3109/02652049309015307

[17]. Goldberg, M., Langer, R., Jia, X. (2007). Nanostructured materials for applications in drug delivery and tissue engineering.Journal of Biomaterials Science, Polymer Edition, 18(3), 241–268. doi:10.1163/156856207779996931

[18]. Mitra, S., Gaur, U., Ghosh, P. C., Maitra, A. N. (2001). Tumourtargeted delivery of encapsulated dextran–doxorubicin conjugates using chitosan nanoparticles as carrier. Journal of Controlled Re-lease, 74(1–3), 317–323. doi:10.1016/S0168-3659(01)00342-X

[19]. Denuziere, A., Ferrier, D., Damour, O., Domard, A. (1998).Chitosan–chondroitin sulfate and chitosan–hyaluronate polyelec-trolyte complexes: biological properties. Biomaterials, 19(14),1275–1285. doi:10.1016/S0142-9612(98)00036-2

[20]. Lim, S. T., Martin, G. P., Berry, D. J., Brown, M. B. (2000).Preparation and evaluation of the in vitro drug release propertiesand mucoadhesion of novel microspheres of hyaluronic acid and chitosan. Journal of Controlled Release, 66(2–3), 281–292.doi:10.1016/S0168-3659(99)00285-0.

[21]. Jaganathan, K. S., Rao, Y. U., Singh, P., Prabakaran, D., Gupta, S., Jain, A., Vyas, S. P. (2005). Development of a single dose tetanus toxoid formulation based on polymeric microspheres: a comparative study of poly (D, L-lactic-co-glycolic acid) versus chitosan microspheres. International Journal of Pharmaceutics, 294(1–2), 23–32. doi:10.1016/j.ijpharm.2004.12.026.

[22]. Calvo, et al. (1997). Novel hydrophilic chitosan-polyethyleneoxide nanoparticles as protein carriers. Journal of Applied Poly-mer Science, 63, 125–132. doi:0021-8995/97/010125-08.

[23]. Tønnesen, H. H., & Karlsen, J. (2002). Alginate in drug delivery systems. Drug Development and Industrial Pharmacy, 28(6),621–630. doi:10.1081/DDC-120003853.

[24]. Rajaonarivony, M., Vauthier, C., Couarraze, G., Puisieux, F., Couvreur, P. (1993). Development of a new drug carrier made from alginate. Journal of Pharmaceutical Sciences, 82(8), 912–917. doi:10.1002/jps.2600820909.

[25]. Pandey, R., Ahmad, Z., Sharma, S., Khuller, G. K. (2005). Nano-encapsulation of azole antifungals: potential applications to improve oral drug delivery. International Journal of Pharmaceutics,301(1–2), 268–276. doi:10.1016/j.ijpharm.2005.05.027.

[26]. Sonvico, F., Cagnani, A., Rossi, A., Motta, S., Di Bari, M. T., Cavatorta, F., Alonso, M. J., Deriu, A., et al. (2006). Formation of self-organized nanoparticles by lecithin/chitosan ionic interaction. The International Journal of Pharmaceutics, 324(1), 67–73. doi:10.1016/j.ijpharm.2006.06.036.

[27]. Roy, K., Mao, H. Q., Huang, S. K., Leong, K. W. (1999). Oral gene delivery with chitosan–DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nature Medicine, 5(4), 387–391. doi:10.1038/7385.

[28]. Tien, C. L., Lacroix, I.-S. P., Mateescu, M. A. (2003). N-acylatedchitosan: hydrophobic matrices for controlled drug release. Jour-nal of Controlled Release, 93(1), 1–13. doi:10.1016/S0168-3659(03)00327-4.

[29]. Teeranachaideekul, V., Muller, R. H., Junyaprasert, V. B. (2007).Encapsulation of ascorbylpalmitate in nanostructured lipid carriers (NLC)—effects of formulation parameters on physicochemical stability. International Journal of Pharmaceutics, 340(1–2),198–206. doi:10.1016/j.ijpharm.2007.03.022.

[30]. Park, J. H., Kwon, S., Nam, J. O., et al. (2005). Self-assemblednanoparticles based on glycol chitosan bearing 5 β-cholanic acidfor RGD peptide delivery. Journal of Controlled Release, 95(3),579–588. doi:10.1016/j.jconrel.2003.12.020.

[31]. Yeh, T. K., Lu, Z., Wientjes, M. G., Au, J. L.-S. (2005). Formulating paclitaxel in nanoparticles alters its disposition. Pharmaceutical Research, 22(6), 867–874. doi:10.1007/s11095-005-4581-4

[32]. Wu, J., Xiaobin, Z., Lee, R. J. (2007). Lipid-based nanoparticu-late drug delivery systems. In D. Thassu, M. Deleers, & Y. Pathak(Eds.), Nanoparticulate drug delivery systems (1st ed.). NewYork: Informa Healthcare USA, Inc.

[33]. Wissing, S. A., & Muller, R. H. (2003). The influence of solidlipid nanoparticles on skin hydration and viscoelasticity—in vivostudy. European Journal of Pharmaceutics and Biopharmaceu-tics, 56(1), 67–72. doi:10.1016/j.addr.2003.12.002.

[34]. Wissing, S. A., Kayser, O., Muller, R. H. (2004). Solid lipidnanoparticles for parenteral drug delivery. Advanced Drug Deliv-ery Reviews, 56(9), 1257–1272. doi:Teeranachaideekul, V., Muller, R. H., Junyaprasert, V. B. (2007).Encapsulation of ascorbylpalmitate in nanostructured lipid carriers (NLC)—effects of formulation parameters on physicochemical stability. International Journal of Pharmaceutics, 340(1–2),198–206. doi:10.1016/j.ijpharm.2007.03.02210.1016/j.addr.2003.12.002.

[35]. Yuan, H., Wang, L. L.,Du, Y. Z., You, J., Hu, F. Q., Zeng, S. (2007).Preparation and characteristics of nanostructured lipid carriers forcontrol-releasing progesterone by melt-emulsification. Colloids and Surfaces. B, Biointerfaces, 60(2), 174–179. doi:10.1016/j.colsurfb.2007.06.011

[36]. Geßner, A., Olbrich, C., Schroder, W., Kayser, O., Muller, R. H.(2001). The role of plasma proteins in brain targeting: species dependent protein adsorption patterns on brain-specific lipid drugconjugate (LDC) nanoparticles. International Journal of Pharma-ceutics, 214(1–2), 87–91. doi:10.1016/S0378-5173(00)00639-6.

[37]. Thevenot, J., TroutierAL, D. L., Delair, T., Ladaviere, C. (2007).Steric stabilization of lipid/polymer particle assemblies by poly(ethylene glycol)-lipids. Bio macromolecules, 8, 3651–3660.doi:10.1021/bm700753q.

[38]. Zhang, L., Chan, J. M., Gu, F. X., Rhee, J. W., Wang, A. Z.,Radovic-Moreno, A. F., et al. (2008). Self-assembled lipid–poly-mer hybrid nanoparticles: a robust drug delivery platform. ACSNano, 2, 1696–1702. doi:10.1021/nn800275r.

[39]. Charcosset, C., El-Harati, A., Fessi, H. (2005). Preparation of solidlipid nanoparticles using a membrane contactor. Journal of Con-trolled Release, 108(1), 112–120. doi:10.1016/j.jconrel.2005.07.023

[40]. Kumar, Sandeep & Dilbaghi, Neeraj & Rani, Ruma & Bhanjana, Gaurav. (2012). Nanotechnology as Emerging Tool for Enhancing Solubility of Poorly Water-Soluble Drugs. BioNanoScience. 2. 10.1007/s12668-012-0060-7.

[41]. Abdellatif A, Alsowinea A. Approved and marketed nanoparticles for disease targeting and applications in COVID-19. Nanotechnology Reviews. 2021;10(1): 1941-1977. https://doi.org/10.1515/ntrev-2021-0115

[42]. Nair, L.S. and C.T. Laurencin, Biodegradable polymers as biomaterials. Progress in Polymer Science, 2007; 32: 762-798.

[43]. Okada, M., Chemical syntheses of biodegradable polymers. Progress in Polymer Science, 2002; 27: 87-133.

[44]. Freiberg, S. and X.X. Zhu, Polymer microspheres for controlled drug release. International Journal of Pharmaceutics, 2004; 282: 1-18.

[45]. Merkli, A., C. Tabatabay, R. Gurny, and J. Heller, Biodegradable polymers for the controlled release of ocular drugs. Progress in Polymer Science, 1998; 23: 563-580.

[46]. Sinha, V.R., K. Bansal, R. Kaushik, R. Kumria, and A. Trehan, Poly-ε-caprolactone microspheres and nanospheres: an overview. International Journal of Pharmaceutics,

[47]. Middleton, J.C. and A.J. Tipton, Synthetic biodegradable polymers as orthopedic devices. Biomaterials, 2000; 21: 2335-46.

[48]. Nair, L.S. and C.T. Laurencin, Biodegradable polymers as biomaterials. Progress in Polymer Science, 2007; 32: 762-798.

[49]. Gunatillake, P., R. Mayadunne, and R. Adhikari, Recent developments in biodegradable synthetic polymers. Biotechnol Annu Rev, 2006; 12: 301-47.

[50]. Erbetta, C.D.A.C., R.J. Alves, J.M. Resende, R.F. de Souza Freitas, and R.G. de Sousa, Synthesis and characterization of poly (D, L-lactide-co-glycolide) copolymer. Journal of Biomaterials and Nanobiotechnology, 2012; 3: 208.

[51]. Merkli, A., C. Tabatabay, R. Gurny, and J. Heller, Biodegradable polymers for the controlled release of ocular drugs. Progress in Polymer Science, 1998; 23: 563-580.

[52]. http://advchempharm.ir/web/2018/07/25/polymeric-nanoparticles-review-of-synthesis-methods-and-applications-in-drug-delivery/

[53]. Pal SL, Jana U, Manna PK, Mohanta GP, Manavalan R. Nanoparticle: An overview of preparation and characterization. Journal of applied pharmaceutical science. 2011 Aug 30(Issue):228-34

[54]. Desgouilles, S.; Vauthier, C.; Bazile, D.; Vacus, J.; Grossiord, J.-L.; Veillard, M.; Couvreur, P. The design of nanoparticles obtained by solvent evaporation: A comprehensive study. Langmuir 2003, 19, 9504–9510. [Google Scholar] [CrossRef]

[55]. Vieira, R.; Souto, S.B.; Sanchez-Lopez, E.; Machado, A.L.; Severino, P.; Jose, S.; Santini, A.; Fortuna, A.; Garcia, M.L.; Silva, A.M.; et al. Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome-Review of Classical and New Compounds: Part-I. Pharmaceuticals 2019, 12, 152. [Google Scholar] [CrossRef][Green Version]leading to nanospheres production

[56]. Jose, S.; Sowmya, S.; Cinu, T.A.; Aleykutty, N.A.; Thomas, S.; Souto, E.B. Surface modified PLGA nanoparticles for brain targeting of Bacoside-A. Eur. J. Pharm. Sci. 2014, 63, 29–35. [Google Scholar] [CrossRef]

[57]. Grumezescu, A.M. Design and Development of New Nanocarriers; William Andrew: Norwich, NY, USA, 2017. [Google Scholar]

[58]. Christine, V.; Ponchel, G. Polymer nanoparticles for nanomedicines. A guide for their design. Anticancer Res. 2017, 37, 1544. [Google Scholar]

[59]. Bohrey, S.; Chourasiya, V.; Pandey, A. Polymeric nanoparticles containing diazepam: Preparation, optimization, characterization, in-vitro drug release and release kinetic study. Nano Converg. 2016, 3, 1–7. [Google Scholar] [CrossRef][Green Version]

[60]. Sharma, N.; Madan, P.; Lin, S. Effect of process and formulation variables on the preparation of parenteral paclitaxel-loaded biodegradable polymeric nanoparticles: A co-surfactant study. Asian J. Pharm. Sci.

2016, 11, 404–416. [Google Scholar] [CrossRef][Green Version]

[61]. Szczęch, M.; Szczepanowicz, K. Polymeric Core-Shell Nanoparticles Prepared by Spontaneous Emulsification Solvent Evaporation and Functionalized by the Layer-by-Layer Method. Nanomaterials 2020, 10, 496. [Google Scholar] [CrossRef][Green Version]

[62]. Kumar, S.; Dilbaghi, N.; Saharan, R.; Bhanjana, G. Nanotechnology as Emerging Tool for Enhancing Solubility of Poorly Water-Soluble Drugs. BioNanoScience 2012, 2, 227–250. [Google Scholar] [CrossRef]

[63]. Souto, E.B.; Souto, S.B.; Campos, J.R.; Severino, P.; Pashirova, T.N.; Zakharova, L.Y.; Silva, A.M.; Durazzo, A.; Lucarini, M.; Izzo, A.A.; et al. Nanoparticle Delivery Systems in the Treatment of Diabetes Complications. Molecules 2019, 24, 4209. [Google Scholar] [CrossRef][Green Version]

[64]. Souto, E.B.; Severino, P.; Santana, M.H.A. Preparação de nanopartículas poliméricas a partir da polimerização de monômeros: Parte I. Polímeros 2012, 22, 96–100. [Google Scholar] [CrossRef][Green Version]

[65]. Guterres, S.S.; Alves, M.P.; Pohlmann, A.R. Polymeric nanoparticles, nanospheres and nanocapsules, for cutaneous applications. Drug Target Insights 2007, 2, 117739280700200002. [Google Scholar] [CrossRef][Green Version]

[66]. Wang, Y.; Li, P.; Truong-Dinh Tran, T.; Zhang, J.; Kong, L. Manufacturing techniques and surface engineering of polymer based nanoparticles for targeted drug delivery to cancer. Nanomaterials 2016, 6, 26. [Google Scholar] [CrossRef][Green Version]

[67]. Lim, K.; Hamid, Z.A.A. 10—Polymer nanoparticle carriers in drug delivery systems: Research trend. In Applications of Nanocomposite Materials in Drug Delivery; Inamuddin, Asiri, A.M., Mohammad, A., Eds.; Woodhead Publishing: Cambridge, UK, 2018; pp. 217–237. [Google Scholar] [CrossRef]

[68]. Reis, C.P.; Neufeld, R.J.; Ribeiro, A.J.; Veiga, F.; Nanoencapsulation, I. Methods for preparation of drug-loaded polymeric nanoparticles. Nanomed. Nanotechnol. Biol. Med. 2006, 2, 8–21. [Google Scholar] [CrossRef][Green Version]

[69]. Pal, S.L.; Jana, U.; Manna, P.K.; Mohanta, G.P.; Manavalan, R. Nanoparticle: An overview of preparation and characterization. J. Appl. Pharm. Sci. 2011, 1, 228–234. [Google Scholar]

[70]. Sánchez-López, E.; Espina, M.; López-Machado, A.; Cano, A.; Busquets, O.; Galindo, R.; Espina, M.; Folch, J.; Souto, E.B.; Calpena, A.C.; et al. Polymeric Nanoparticles for the Treatment of Neurodegenerative Diseases. In Alzheimer ’s Disease and Glaucoma; Trends in Pharmaceutical and Food Sciences I, Cajal, Y., Muñoz-Torrero, D., Ciudad, C.J., Valles, J., Eds.; Open Access Journal of Pharmaceutical Research, Medwin Publishers: Troy, MI, USA, 2020; ISSN 2574-7797. Chapter 7; pp. 68–76. [Google Scholar]

[71]. Araujo, J.; Vega, E.; Lopes, C.; Egea, M.A.; Garcia, M.L.; Souto, E.B. Effect of polymer viscosity on physicochemical properties and ocular tolerance of FB-loaded PLGA nanospheres. Colloids Surf. B Biointerfaces 2009, 72, 48–56. [Google Scholar] [CrossRef]

[72]. Canadas, C.; Alvarado, H.; Calpena, A.C.; Silva, A.M.; Souto, E.B.; Garcia, M.L.; Abrego, G. In vitro, ex vivo and in vivo characterization of PLGA nanoparticles loading pranoprofen for ocular administration. Int. J. Pharm. 2016, 511, 719–727. [Google Scholar] [CrossRef]

[73]. Sanchez-Lopez, E.; Egea, M.A.; Cano, A.; Espina, M.; Calpena, A.C.; Ettcheto, M.; Camins, A.; Souto, E.B.; Silva, A.M.; Garcia, M.L. PEGylated PLGA nanospheres optimized by design of experiments for ocular administration of dexibuprofen-in vitro, ex vivo and in vivo characterization. Colloids Surf. B Biointerfaces 2016, 145, 241–250. [Google Scholar] [CrossRef][Green Version]

[74]. Sanchez-Lopez, E.; Egea, M.A.; Davis, B.M.; Guo, L.; Espina, M.; Silva, A.M.; Calpena, A.C.; Souto, E.M.B.; Ravindran, N.; Ettcheto, M.; et al. Memantine-Loaded PEGylated Biodegradable Nanoparticles for the Treatment of Glaucoma. Small 2018, 14. [Google Scholar] [CrossRef]

[75]. Sanchez-Lopez, E.; Ettcheto, M.; Egea, M.A.; Espina, M.; Cano, A.; Calpena, A.C.; Camins, A.; Carmona, N.; Silva, A.M.; Souto, E.B.; et al. Memantine loaded PLGA PEGylated nanoparticles for Alzheimer's disease: In vitro and in vivo characterization. J. Nanobiotechnol. 2018, 16, 32. [Google Scholar] [CrossRef]

[76]. Salatin, S.; Barar, J.; Barzegar-Jalali, M.; Adibkia, K.; Kiafar, F.; Jelvehgari, M. Development of a nanoprecipitation method for the entrapment of a very water soluble drug into Eudragit RL nanoparticles. Res. Pharm. Sci. 2017, 12, 1. [Google Scholar] [CrossRef][Green Version]

[77]. Martinez Rivas, C.J.; Tarhini, M.; Badri, W.; Miladi, K.; Greige-Gerges, H.; Nazari, Q.A.; Galindo Rodriguez, S.A.; Roman, R.A.; Fessi, H.; Elaissari, A. Nanoprecipitation process: From encapsulation to drug delivery. Int. J. Pharm. 2017, 532, 66–81. [Google Scholar] [CrossRef]

[78]. Chidambaram, M.; Krishnasamy, K. Modifications to the conventional nanoprecipitation technique: An approach to fabricate narrow sized polymeric nanoparticles. Adv. Pharm. Bull. 2014, 4, 205. [Google Scholar] [PubMed]

[79]. Guterres, S.S.; Alves, M.P.; Pohlmann, A.R. Polymeric nanoparticles, nanospheres and nanocapsules, for cutaneous applications. Drug Target Insights 2007, 2, 117739280700200002. [Google Scholar] [CrossRef][Green Version]

[80]. Zielińska A, Carreiró F, Oliveira AM, Neves A, Pires B, Venkatesh DN, Durazzo A, Lucarini M, Eder P, Silva AM, Santini A, Souto EB. Polymeric Nanoparticles: Production, Characterization, Toxicology and Ecotoxicology. Molecules. 2020; 25(16):3731. https://doi.org/10.3390/molecules25163731

[81]. Zielińska, A. et al. Polymeric Nanoparticles: Production, Characterization, Toxicology and Ecotoxicology. Molecules 25, 3731 (2020).

[82]. Fornaguera, C. & Solans, C. Analytical Methods to Characterize and Purify Polymeric Nanoparticles. Int. J. Polym. Sci. 2018, (2018).

[83]. Aslı Katmıs, Serap Fide, Seyma Karaismailoglu, S. D. Synthesis and characterization methods of polymeric nanoparticles. 2, 1–9 (2019).

[84]. Carina I.C. Crucho, M. T. B. Polymeric nanoparticles : A study on the preparation variables and characterization methods. Mater. Sci. Eng. C 80, 771–784 (2017).

[85]. Zielińska, A. et al. Polymeric Nanoparticles: Production, Characterization, Toxicology and Ecotoxicology. Molecules 25, 3731 (2020).

[86]. Anwer Md. K., Al-Shdefat Ramadan, Ezzeldin Essam, Alshahrani Saad M., Alshetaili Abdullah S., I. M. Preparation , Evaluation and Bioavailability Studies of Eudragit Coated PLGA Nanoparticles for Sustained Release of Eluxadoline for the Treatment of Irritable Bowel Syndrome. Front. Pharmacol. 8, (2017).

[87]. Ramalho, M. J. & Pereira, M. C. Preparation and Characterization of Polymeric Nanoparticles: An Interdisciplinary Experiment. Journel Chem. Educ. 93, 1446–1451 (2016).

[88]. Fornaguera, C. & Solans, C. Analytical Methods to Characterize and Purify Polymeric Nanoparticles. Int. J. Polym. Sci. 2018, (2018)

[89]. Qasim M, Udomluck N, Chang J, Park H, K. K. Antimicrobial activity of silver nanoparticles encapsulated in poly-N-isopropylacrylamide-based polymeric nanoparticles. Int. J. Nanomedicine 13, 235–249 (2018).

[90]. Aslı Katmıs, Serap Fide, Seyma Karaismailoglu, S. D. Synthesis and characterization methods of polymeric nanoparticles. 2, 1–9 (2019).

[91]. Carina I.C. Crucho, M. T. B. Polymeric nanoparticles : A study on the preparation variables and characterization methods. Mater. Sci. Eng. C 80, 771–784 (2017)

[92]. Techniques for the characterisation of Polymeric Nanoparticles https://www.cademix.org/techniques-for-characterization-of-polymeric-nanoparticles-a-review/18 Feb, 2023

[93]. Pandey V, Haider T, Agrawal P, Soni S, Soni V. Advances in Natural Polymeric Nanoparticles for the Drug Delivery.

Advances in Drug Delivery Methods [Working Title] [Internet]. 2022 Oct 31; Available from: http://dx.doi.org/10.5772/intechopen.107513

[94]. Yoo, H. S., Lee, J. E., Chung, H., Kwon, I. C., Jeong, S. Y. (2005).Self -assembled nanoparticles containing hydrophobically modifiedglycol chitosan for gene delivery. Journal of Controlled Release,103(1), 235–243. doi:10.1016/j.jconrel.2004.11.033.